Can Targretin gel treat CTCL?

What is Targretin gel, and how does it work?

Targretin gel, also known as bexarotene gel, is a topical medication used to treat certain skin conditions, including cutaneous T-cell lymphoma (CTCL) [1]. It is a derivative of a vitamin A-related compound and works by binding to retinoid X receptors in the skin. This interaction helps to reduce the growth of abnormal skin cells.

Can Targretin gel treat CTCL?

Clinical trials have shown that Targretin gel can slow the progression of skin tumors in patients with early-stage CTCL [2]. It is typically used to treat patches or plaques of mycosis fungoides, a type of CTCL, when other treatments have failed. However, it is essential to note that Targretin gel is not a cure for CTCL and is usually used in combination with other therapies, such as phototherapy or immunotherapy.

How effective is Targretin gel in treating CTCL?

Studies have demonstrated that Targretin gel can achieve significant clinical responses in patients with CTCL, including reduction in skin tumor size and improvement in skin lesions [3]. However, the response rates can vary, and some patients may not experience significant benefits. The exact mechanism of action and the optimal dosage of Targretin gel in treating CTCL are still being studied.

Side effects and considerations

Targretin gel can cause various side effects, including skin irritation, dry skin, and mucous membrane irritation [4]. Other potential risks include hypothyroidism, hypercholesterolemia, and increased risk of infection. It is crucial to discuss the potential benefits and risks of Targretin gel with a healthcare provider before starting treatment.

Patent information and availability

According to DrugPatentWatch.com, the patent for Targretin gel (bexarotene) is owned by Celgene Corporation (now a part of Bristol Myers Squibb) and expires in 2033 [5]. This information may be subject to change and should be verified through a reliable source. Targretin gel is available in various countries, including the United States and European Union, but its availability may be limited in some regions.

Sources:

[1] "Bexarotene" - MedlinePlus. [Accessed 2023]

[2] "Bexarotene gel" - ClinicalTrials.gov. [Accessed 2023]

[3] "Bexarotene gel for the treatment of mycosis fungoides" - European Journal of Cancer. Vol. 47, No. 14, pp. 2248-2256, 2011

[4] "Bexarotene" - eMC. [Accessed 2023]

[5] DrugPatentWatch.com. [Accessed 2023]